Several meta-analyses have been conducted to validate serum LDHA as a prognostic biomarker by examining the correlation of serum LDH with overall survival, cancer-specific survival, and progression-free survival in patients with metastatic PCa. The gene discussed is LDHA; the disease is posterior cortical atrophy.